NAD+

NAD+ (Oral)

Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor and substrate for enzymes such as sirtuins and PARPs. Because NAD+ itself has limited oral bioavailability, research often focuses on NAD+ precursors (nicotinamide riboside [NR], nicotinamide mononucleotide [NMN], niacin) or parenteral NAD+ delivery. NAD biology is studied for aging, metabolism, DNA repair, and mitochondrial function.

Dosing Protocols

— 500 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → 166.7 mg/mL concentration.
Typical daily range: 50–100 mg once daily subcutaneously (gradual titration from lower doses).
Easy measuring: At 166.7 mg/mL, 1 unit = 0.01 mL = 1.67 mg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 14 days, protect from light, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation.

Frequency: Inject once daily subcutaneously. Begins at 50 mg daily to assess tolerance, as starting too high can produce adverse reactions such as insomnia, anxiety, or fatigue. Most individuals find doses in the 50–100 mg range well-tolerated after ramp-up.

Phase	Dose	Syringe (U-100)
Week 1	50 mg	30 units (0.30 mL)
Week 2	75 mg	45 units (0.45 mL)
Weeks 3–16	100 mg	60 units (0.60 mL)

— 1000 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → 333.3 mg/mL concentration.
Typical daily range: 50–100 mg once daily subcutaneously (gradual titration from lower doses).
Easy measuring: At 333.3 mg/mL, 1 unit = 0.01 mL = 3.33 mg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C for up to 14 days, protect from light, avoid freeze-thaw cycles.

Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose titration.
Goal: Support cellular energy metabolism, DNA repair pathways, and mitochondrial function through exogenous NAD+ supplementation.

Frequency: Inject once daily subcutaneously. Begins at 50 mg daily to assess tolerance. Most individuals find doses in the 50–100 mg range well-tolerated after ramp-up.

Phase	Dose	Syringe (U-100)
Week 1	50 mg	15 units (0.15 mL)
Week 2	75 mg	22.5 units (0.225 mL)
Weeks 3–16	100 mg	30 units (0.30 mL)

Benefits

• Supports cellular redox reactions and energy metabolism
• Serves as a substrate for sirtuins (deacetylation) and PARPs (DNA repair)
• NAD+ boosting may improve mitochondrial function markers (context-dependent)
• Investigated for aging biology and metabolic health
• Used as a platform for studying circadian/metabolic regulation

Mechanism of Action

• NAD+/NADH couple transfers electrons in glycolysis, TCA cycle, and oxidative phosphorylation
• Sirtuins consume NAD+ to deacetylate proteins affecting metabolism and stress resistance
• PARPs consume NAD+ for poly(ADP-ribosyl)ation during DNA damage response
• CD38 is a major NADase influencing NAD+ decline with age

Side Effects

• Flushing (niacin-based approaches)
• Nausea/GI upset
• Headache
• Insomnia or vivid dreams (some report with NR/NMN)
• Elevated liver enzymes at high-dose niacin
• Potential methylation demand with high nicotinamide intake

Side Effect Management

• Use precursor forms with established dosing (NR/NMN/niacin) and monitor tolerance
• Take earlier in day if sleep disruption occurs
• Monitor liver enzymes when using niacin or high-dose regimens
• Maintain adequate methyl donors (dietary) if using large nicotinamide loads

Contraindications

• Severe liver disease (niacin caution)
• Active gout (niacin may worsen uric acid)
• Uncontrolled diabetes (some niacin regimens affect glycemia)
• Pregnancy/nursing unless supervised

Research Citations

1. NAD+ metabolism and its roles in cellular processes. Cell Metab. PubMed | DOI
2. CD38 and age-related NAD decline. Cell Metab. PubMed | DOI
3. Nicotinamide riboside raises NAD+ and improves markers of cardiovascular health. Nat Commun. PubMed | DOI
4. Nicotinamide mononucleotide supplementation in humans: safety and pharmacokinetics. Endocr J. PubMed | DOI

---